Abstract:Background and Aims: Myasthenia gravis (MG) is a T-cell dependent antibody-mediated autoimmune disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen, comprising several T and B cell auto-epitopes. We hypothesized that an efficacious drug candidate for antigen-specific therapy in MG should comprise a broad range of these auto-epitopes and be administered in a noninflammatory and tolerogenic context. Methods: We used a soluble mutated form of the extracellular domain of the α1 chain of the AChR (α1-ECD m ), which represents the major portion of auto-epitopes involved in MG, and investigated, in a well-characterized rat model of experimental autoimmune myasthenia gravis (EAMG) whether its intravenous administration could safely and efficiently treat the autoimmune disease. Results: We demonstrated that intravenous administration of α1-ECD m abrogates established EAMG, in a dose and time dependent manner, as assessed by clinical symptoms, body weight, and compound muscle action potential (CMAP) decrement. Importantly, the effect was more pronounced compared to drugs representing current standard of care for MG. The protein had a short plasma half-life, most of what could be recovered was sequestered in the liver, kidneys and spleen. Further, we did not observe any signs of toxicity or intolerability in animals treated with α1-ECD m. Conclusion: We conclude that intravenous treatment with α1-ECD m is safe and effective in suppressing EAMG. α1-ECD m is in preclinical development as a promising new drug candidate for MG.

Inhibition of Sera from Patients with Myasthenia Gravis to the Binding of Acetylcholine Receptor by a Fusion Protein of Antibody Fragment and Albumin

Suppressive Effect of the Single Chain Antibody Against Acetylcholine Receptor on the Binding Activity of the Pathogenic Antibodies

Fusion Protein of Single-Chain Variable Domain Fragments for Treatment of Myasthenia Gravis

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Antigen-specific Immunoadsorption of Anti-acetylcholine Receptor Antibodies from Sera of Patients with Myastenia Gravis

Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.

Construction and Expression of a Fusion Protein of Scfv Against Human Acetylcholine Receptor-Human Serum Albumin in E.coli

Preparation of an immunoadsorbent coupled with a recombinant antigen to remove anti-acetylcholine receptor antibodies in abnormal serum.

Selective Recognition and Elimination of Nicotinic Acetylcholine Receptor-Reactive B Cells by A Recombinant Fusion Protein Achr-Fc in Myasthenia Gravis in Vitro

Construction and Characterization of a Human Anti-Acetylcholine Receptor Autoantibody

Artificial Construction of Human Pathogenic Autoantibody in Myasthenia Gravis

Removal of Complement Binding Activity of an Anti-Acetylcholine Receptor Antibody by Site Directed Mutagenesis

Preparation of Specific Immunoadsorbent in Myasthenia Gravis and Its Adsorption Effect for the Sera of the Patients

Construction of the Fusion Gene of Single Chain Antibody Against Human Acetylcholine Receptor with Human Serum Albumin

Characterization of Expressed Anti-Cetylcholine Receptor Single Chain Variable Fragment in Pichia Pastoris

Construction of Gene of Single Chain Variable Fragment Against Acetylcholine Receptor in Myasthenia Gravis

Preparation of specific immunoadsorbent in myasthenia gravis and its dynamic absorption test on the patients' sera

Potential Roles of Recombinant Acetylcholine Receptor Α Subunit 1–211 in Immunoadsorbent and DNA Immunization

A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

PATHOGENICITY AND SEQUENCE ANALYSIS OF A MOUSE MONOCLONAL ANTIBODY AGAINST HUMAN ACETYLCHOLINE RECEPTOR IN MYASTHENIA GRAVIS